VALNEVA to Conduct Investor and Partnering Meetings during the Annual J.P. Morgan Healthcare Conference
04 Décembre 2017 - 7:01PM
Valneva to Conduct Investor and
Partnering Meetings during the Annual J.P. Morgan Healthcare
Conference
Lyon (France), December 4, 2017 - Valneva SE
today announces that its senior management team will hold investor
and partnering meetings in San Francisco during the 36th Annual
J.P. Morgan Healthcare Conference.
The Company will notably provide an update on
its commercial business as well as the development of its Lyme
disease vaccine candidate.
To schedule a meeting with Valneva, investors
attending the conference can registeron the online system managed
by the Company's US investor relations firm or contact Valneva's
Head of IR directly at investors@valneva.com.
About Valneva SE
Valneva is a fully integrated, commercial stage
biotech company focused on developing innovative life-saving
vaccines.
Valneva's portfolio includes two commercial
vaccines for travelers: IXIARO®/JESPECT® indicated for the
prevention of Japanese encephalitis and DUKORAL® indicated for the
prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC. The Company has proprietary vaccines in
development including a unique vaccine against Lyme disease. A
variety of partnerships with leading pharmaceutical companies
complement the Company's value proposition and include vaccines
being developed using Valneva's innovative and validated technology
platforms (EB66® cell line and IC31® adjuvant).
Valneva shares are tradable on Euronext-Paris,
the Vienna stock exchange and Deutsche Börse's electronic platform
Xetra®. The Company has operations in France, Austria, Great
Britain, Sweden, Canada and the US with over 400 employees. More
information is available at www.valneva.com.
Valneva Investor and
Media Contacts Laetitia Bachelot Fontaine Global Head of
Investor Relations & Corporate Communications T +33 (0)2 2807
1419 M +33 (0)6 4516 7099 investors@valneva.com |
Nina Waibel
Corporate Communications Specialist T +43 1206 201 149 M +43
6768 455 6719 Communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/ff2eb187-4f2b-4545-893f-3a454aa4bad0